Project 2021

Australia

About Project 2021 Australia

Project Twenty21 Australia is a collaboration between the ACCM and Drug Science Org in the UK. Project Twenty21 is already underway in the UK (https://www.drugscience.org.uk/).  Project Twenty21 Australia is the Australian arm of this project, where data will be collected in an Australian population in four of the eight clinical conditions being investigated in the UK. These clinical conditions will be:

  • chronic pain
  • anxiety
  • post-traumatic stress disorder (PTSD)
  • multiple sclerosis (MS)

Project Twenty21 Australia is an open-label, prospective observational cohort study. It will follow patients prescribed medicinal cannabis in Releaf Clinics for the above-mentioned conditions over 12 months, collecting data on efficacy, safety and tolerability. The study will collect ‘real world data’ since it is measuring outcome variables over an extended time-period and the medicinal cannabis products will be individualised to the participants. Medicinal cannabis products prescribed to study participants are chosen from a select range of products and will be available at a discounted price to study participants for the duration of their participation in the study. The study will begin in January 2022. Visit drugscience.org.uk  for information on the UK study.

For further information, see the Participant Information Form and/or contact the Study Coordinator Ms Michelle Frans (registered nurse) via email: michelle@releafgroupltd.com or call (03) 9016 9094.